Ensuring ethical participation in Clinical Trials through informed consent

Volunteers are indispensable in clinical trials, and their informed consent serves as the cornerstone of ethical research. This consent is not merely a formality; it represents an ongoing conversation between the research team and participants. The process involves clearly educating potential volunteers about the study, addressing any concerns, and providing answers to their questions. By fully understanding and agreeing to the trial’s conditions, participants help advance medical knowledge while being protected from potential risks.

Informed consent is a foundational element of research ethics. It entails providing patients with comprehensive information, including potential risks and benefits, about a medical procedure, treatment, clinical trial, or genetic testing. This allows patients to make informed decisions about whether to proceed with treatment, undergo testing, or participate in a trial.

In clinical trials, informed consent requires that volunteers make an educated decision about their participation. They must be informed about the procedures they will undergo, how the research plan works, potential risks or discomforts, and the voluntary nature of their involvement. This information is conveyed during the informed consent process, ensuring that participants are fully aware of what to expect.

Potential volunteers are provided with detailed information about the research, its purpose, duration, the voluntary nature of participation, procedures involved, potential benefits and risks, discomforts, alternative treatments, privacy protection, and the participant’s rights, including the right to withdraw from the trial at any time. It is crucial for participants to thoroughly review this information, as it helps them understand the risks and safety aspects of the trial. They are also encouraged to ask any questions they may have during this process.

Informed consent is vital to ensure that participants have a comprehensive understanding of all aspects of their involvement in a clinical trial. This understanding fosters trust, transparency, and a smooth trial process, as well-informed participants are more likely to cooperate and engage responsibly. For research staff, informed consent ensures ethical adherence and contributes to the trial’s success while protecting participants’ well-being and the research’s integrity.

The informed consent process is governed by four key principles: decision-making capacity, disclosure, documentation of consent, and competency. Decision-making capacity ensures that participants can make informed decisions by understanding their options, the consequences, and the personal costs and benefits relative to their values. If a participant lacks this capacity, a surrogate decision-maker may be involved. Disclosure involves providing sufficient information to the participant, including risks, benefits, and clear answers to questions, enabling them to make an informed decision.

Documenting consent is essential, particularly for procedures with significant risks. This typically involves a written consent form, supported by a verbal explanation, and must be signed by both the participant and the doctor. Competency ensures that participants possess the mental and emotional capacity to understand the trial and make informed decisions.

Informed consent is obtained before any trial-specific activity begins and is documented by a signed consent form. This document is retained for the trial’s duration and beyond for auditing purposes. Informed consent is an ongoing process, requiring continuous communication between research staff and participants, especially if new information emerges that could impact the participant’s willingness to continue.

In clinical trials, informed consent is obtained through paper or electronic forms, which are reviewed for clarity and completeness by trained individuals. At FluCamp, for instance, participants complete paper consent forms in person, guided by trained staff who review the details and answer any questions.

Understanding the importance of informed consent and the principles that support it ensures that participants are well-informed and ethically engaged in clinical trials, contributing to the advancement of medical research.

Informed consent is the cornerstone of ethical research, ensuring that clinical trial participants are well-informed, protected, and actively engaged in the advancement of medical knowledge.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring